Longest survival follow-up ever reported for immunotherapy treatment in this setting
Global Phase-3 study initiation expected in the second half of 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Sun Pharma's Dadra facility receives OAI status from US FDA
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated
